Nov 29 (Reuters) - Vivos Therapeutics said on Wednesday the U.S. health regulator has cleared its oral device treatment for severe obstructive sleep apnea (OSA). (Reporting by Pratik Jain in Bengaluru; Editing by Shilpi Majumdar)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.125 USD | -2.97% | -19.20% | -82.92% |
Apr. 01 | Signs of Softening Inflation Fuel Narrow Premarket Gains for US Equity Futures | MT |
Apr. 01 | Top Premarket Decliners | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-82.92% | 6.34M | |
+73.46% | 12.41B | |
-15.61% | 8.23B | |
+3.88% | 6.46B | |
+14.69% | 5.5B | |
-5.53% | 5.33B | |
+42.58% | 5.1B | |
-32.61% | 2.54B | |
+10.80% | 1.99B | |
-0.74% | 1.99B |
- Stock Market
- Equities
- VVOS Stock
- News Vivos Therapeutics, Inc.
- US FDA clears Vivos Therapeutics' oral device treatment for sleep apnea